Athira Pharma Advances ATH-1105 Clinical Trial for ALS Treatment

Tuesday, 11 June 2024, 08:20

Discover the latest advancement in Athira Pharma's Phase 1 clinical trial of ATH-1105, a promising oral drug candidate designed for the treatment of Amyotrophic Lateral Sclerosis (ALS). With the completion of the first cohort, the results signal a significant step forward in the development of potential therapies for ALS. The progress made in the trial holds the potential to positively impact the future treatment landscape for ALS patients.
https://store.livarava.com/b1aa60d7-27e5-11ef-a412-9d5fa15a64d8.jpg
Athira Pharma Advances ATH-1105 Clinical Trial for ALS Treatment

Athira Pharma Progresses in Phase 1 Clinical Trial of ATH-1105 for ALS Treatment

Athira Pharma has achieved a milestone by completing the first cohort in the Phase 1 clinical trial of ATH-1105, a small molecule drug candidate aimed at treating Amyotrophic Lateral Sclerosis (ALS).

Key Highlights:

  • Advancement: Progress made in the clinical trial marks a significant step towards developing a potential treatment for ALS.
  • Promising Candidate: ATH-1105, an oral small molecule drug, shows promise in the treatment of ALS.
  • Impact: Positive results from the trial could lead to improved therapeutic options for ALS patients.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe